Us Congress 2025-2026 Regular Session

Us Congress House Bill HB890 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1	I
2	2	119THCONGRESS
3	3	1
4	4	STSESSION H. R. 890
5	5	To amend title 35, United States Code, to prevent double patenting, and
6	6	for other purposes.
7	7	IN THE HOUSE OF REPRESENTATIVES
8	8	JANUARY31, 2025
9	9	Mr. R
10	10	YANintroduced the following bill; which was referred to the Committee
11	11	on the Judiciary
12	12	A BILL
13	13	To amend title 35, United States Code, to prevent double
14	14	patenting, and for other purposes.
15	15	Be it enacted by the Senate and House of Representa-1
16	16	tives of the United States of America in Congress assembled, 2
17	17	SECTION 1. SHORT TITLE. 3
18	18	This Act may be cited as the ‘‘Stopping Pharma’s 4
19	19	Ripoffs and Drug Savings For All Act’’. 5
20	20	SEC. 2. PREVENTION OF DOUBLE PATENTING. 6
21	21	(a) I
22	22	NGENERAL.—Section 253 of title 35, United 7
23	23	States Code, is amended by adding at the end the fol-8
24	24	lowing: 9
25	25	‘‘(c) D
26	26	ISCLAIMERS OFDRUGPATENTTERM.— 10
27	27	VerDate Sep 11 2014 02:38 Feb 28, 2025 Jkt 059200 PO 00000 Frm 00001 Fmt 6652 Sfmt 6201 E:\BILLS\H890.IH H890
28	28	kjohnson on DSK7ZCZBW3PROD with $$_JOB 2
29	29	•HR 890 IH
30	30	‘‘(1) IN GENERAL.—Except as provided in para-1
31	31	graph (2), in a proceeding challenging the validity of 2
32	32	patents under section 505(c) of the Federal Food, 3
33	33	Drug, and Cosmetic Act (21 U.S.C. 355(c)) with re-4
34	34	spect to a drug, under section 351(l) of the Public 5
35	35	Health Service Act (42 U.S.C. 262(l)) with respect 6
36	36	to a biological product, or a Federal district court 7
37	37	proceeding involving patents that are the subject of 8
38	38	an action under section 271(e)(2), the patentee shall 9
39	39	be presumed to have disclaimed the patent term for 10
40	40	each of the listed patents after the date on which the 11
41	41	term of the first patent expires, subject to the excep-12
42	42	tions provided for in subsection (2). 13
43	43	‘‘(2) D
44	44	EMONSTRATION OF DISTINCT INVEN -14
45	45	TIONS.—If a patentee demonstrates by a preponder-15
46	46	ance of the evidence that certain patents described 16
47	47	in paragraph (1) cover patentably distinct inventions 17
48	48	from the invention claimed in the first such patent 18
49	49	to expire, no part of the term of any such patent 19
50	50	shall be presumed to have been disclaimed, and all 20
51	51	patent term extensions granted by the United States 21
52	52	Patent and Trademark Office shall be respected, un-22
53	53	less and to the extent the patentee expressly dis-23
54	54	claims, in writing, the patent term for each such 24
55	55	patent.’’. 25
56	56	VerDate Sep 11 2014 02:38 Feb 28, 2025 Jkt 059200 PO 00000 Frm 00002 Fmt 6652 Sfmt 6201 E:\BILLS\H890.IH H890
57	57	kjohnson on DSK7ZCZBW3PROD with $$_JOB 3
58	58	•HR 890 IH
59	59	(b) USPTO REVIEW.— 1
60	60	(1) D
61	61	EFINITIONS.—In this subsection— 2
62	62	(A) the term ‘‘Office’’ means the United 3
63	63	States Patent and Trademark Office; and 4
64	64	(B) the term ‘‘Director’’ means the Under 5
65	65	Secretary of Commerce for Intellectual Property 6
66	66	and Director of the Office. 7
67	67	(2) R
68	68	EVIEW.—The Director shall conduct a 8
69	69	comprehensive review of the patent examination pro-9
70	70	cedures of the Office to determine whether the Of-10
71	71	fice— 11
72	72	(A) is using best examination practices, 12
73	73	guidance, and procedures to avoid the issuance 13
74	74	of patents relating to the same drug, or biologi-14
75	75	cal product, that are not patentably distinct 15
76	76	from one another, and not subject to an appro-16
77	77	priate disclaimer of patent term; and 17
78	78	(B) should develop and implement new 18
79	79	practices, guidance, or procedures to— 19
80	80	(i) improve examination of patent ap-20
81	81	plications relating to the same drug or bio-21
82	82	logical product; and 22
83	83	(ii) reduce the improper issuance of 23
84	84	patents that improperly extend the term of 24
85	85	VerDate Sep 11 2014 02:38 Feb 28, 2025 Jkt 059200 PO 00000 Frm 00003 Fmt 6652 Sfmt 6201 E:\BILLS\H890.IH H890
86	86	kjohnson on DSK7ZCZBW3PROD with $$_JOB 4
87	87	•HR 890 IH
88	88	exclusivity afforded a new drug or biologi-1
89	89	cal product. 2
90	90	(3) R
91	91	EPORT.—Not later than 1 year after the 3
92	92	date of enactment of this Act, the Director shall 4
93	93	submit to the Committee on the Judiciary of the 5
94	94	House of Representatives a report that contains— 6
95	95	(A) the findings from the review conducted 7
96	96	under paragraph (2); and 8
97	97	(B) any recommendations of the Director 9
98	98	with respect to the review conducted under 10
99	99	paragraph (2). 11
100	100	Æ
101	101	VerDate Sep 11 2014 02:38 Feb 28, 2025 Jkt 059200 PO 00000 Frm 00004 Fmt 6652 Sfmt 6301 E:\BILLS\H890.IH H890
102	102	kjohnson on DSK7ZCZBW3PROD with $$_JOB